<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00234091</url>
  </required_header>
  <id_info>
    <org_study_id>CIPRA TH001</org_study_id>
    <secondary_id>PREDICT</secondary_id>
    <secondary_id>10409</secondary_id>
    <nct_id>NCT00234091</nct_id>
  </id_info>
  <brief_title>When to Start Anti-HIV Drugs in Children Infected With HIV (The PREDICT Study)</brief_title>
  <official_title>An Open Label, Randomized Study to Compare Antiretroviral Therapy (ART) Initiation When CD4 is Between 15% to 24% to ART Initiation When CD4 Falls Below 15% in Children With HIV Infection and Moderate Immune Suppression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Comprehensive International Program of Research on AIDS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine when HIV infected children should begin taking
      anti-HIV medications in order to improve both patient quality of life and survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of highly active antiretroviral therapy (HAART) has resulted in a significant
      reduction in AIDS-related deaths and complications among adults and adolescents. However, the
      medical management of HIV infected children remains challenging. Access to HIV treatment is
      limited and early treatment initiation can cause serious complications. Since there is
      currently no cure for HIV, a balance between treating the disease and maintaining quality of
      life must be weighed carefully. An evaluation to determine the appropriate time to initiate
      HAART is necessary to improve both quality of life and survival for HIV infected children.

      This study will last 144 weeks. All participants will have a CD4 percentage (CD4%) between
      15% and 24% and will be randomly assigned to either receive immediate or delayed HAART. The
      HAART regimen will consist of two nucleoside reverse transcriptase inhibitors, zidovudine and
      lamivudine. In addition, participants will also receive either one non-nucleoside reverse
      transcriptase inhibitor, nevirapine or efavirenz, or one protease inhibitor,
      ritonavir-boosted lopinavir or nelfinavir. Abacavir will replace zidovudine or lamivudine if
      participants experience toxicity to the regimen. Participants in the immediate treatment arm
      will receive HAART on Day 1 of the study regardless of their CD4%. Participants in the
      delayed treatment arm will receive HAART if their CD4% falls below 15 or if they develop a
      CDC Category C illness.

      Study visits will occur every 4 weeks for the first 12 weeks and then every 12 weeks until
      the end of the study. Blood collection, physical exams, and medical and medication history
      reviews will occur at all visits. Adherence, quality of life, and lipodystrophy assessments
      will occur every 12 weeks for participants on HAART. Participants will be encouraged to
      enroll in a related substudy to examine the neurodevelopment of HIV infected children.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AIDS-free survival</measure>
    <time_frame>Week 144</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Direct and indirect cost of treatment per patient</measure>
    <time_frame>Week 144</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and duration of hospitalizations</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to and number of Grades 3 or 4 HAART-related toxicity and intolerance</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of HAART regimen changes</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Grades 1 or 2 infectious episodes</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of courses of antibiotics used</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of HIV-related clinical events</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic failure, defined as HIV viral load of 1000 copies/ml</measure>
    <time_frame>Week 24 after HAART initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of a resistance mutation in participants with virologic failure</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of growth in Z scores</measure>
    <time_frame>study entry to Week 144</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD4% and time-weighted average change</measure>
    <time_frame>study entry and Week 144</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 less than 10%</measure>
    <time_frame>Week 144</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average scores of the child's quality of life over time</measure>
    <time_frame>Week 144</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage adherence to HAART over time by pill count/weighing liquid medication bottles, self report, and questionnaire</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of iron deficiency anemia</measure>
    <time_frame>study entry and Weeks 24, 48, 72, 96, 120, and 144</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV viral sequence</measure>
    <time_frame>study entry and treatment failure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV viral replication capacity</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytotoxic T-cell (CTL) response</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of different T-cell subsets</measure>
    <time_frame>study entry and Weeks 48, 96, and 144</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Immediate treatment; individuals receive HAART on Day 1 of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Delayed treatment; individuals receive HAART if their CD4 percentage falls below 15 percentage OR if they develop a CDC category C illness</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abacavir</intervention_name>
    <description>8 mg/kg (up to 300 mg/dose) take orally twice daily</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
    <description>200 to 600 mg taken orally once daily</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>4 mg/kg (up to 150 mg/dose) taken orally twice daily</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/Ritonavir</intervention_name>
    <description>230 mg/57.5 mg/m^2 body surface area taken orally twice daily with food</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nelfinavir</intervention_name>
    <description>45-55 mg/kg taken orally twice daily with food</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine</intervention_name>
    <description>120 mg/m^2 once daily for first 14 days, tehn 200 mg/m^2 (up to 400 mg/day) twice daily</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
    <description>180-240 mg/m^2 every 12 hours (up to 300 mg/dose)</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infected

          -  Antiretroviral naive, defined as never receiving anti-HIV medications, receiving them
             for less than 7 days, or only receiving them to prevent mother-to-child transmission
             (MTCT)

          -  CD4% between 15 and 24 within 30 days prior to study entry

          -  CDC pediatric clinical classification A or B

          -  Parent or guardian willing to provide informed consent and willing to follow all study
             procedures and requirements

        Exclusion Criteria:

          -  Use of systemic chemotherapy, immunomodulators, HIV vaccines, immune globulin,
             interleukins, or interferons within 30 days prior to study entry

          -  Active AIDS-defining illnesses (CDC Category C) within 30 days prior to study entry

          -  Certain abnormal laboratory values

          -  Known kidney disease

          -  Known allergy or sensitivity to study drugs

          -  Require certain medications

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kiat Ruxrungtham, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Medicine at Chulalongkorn University, Bangkok, Thailand</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Saphonn Vonthanak, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>National Center for HIV/AIDS, Dermatology, and STDs, Phnom Penh, Cambodia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Pediatric Hosp., Cambodia CIPRA CRS</name>
      <address>
        <city>Phnom Penh</city>
        <country>Cambodia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Social Health Clinic, Cambodia CIPRA CRS</name>
      <address>
        <city>Phnom Penh</city>
        <country>Cambodia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hiv-Nat Cipra Crs</name>
      <address>
        <city>Pathumwan</city>
        <state>Bangkok</state>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiang Rai Regional Hosp. CIPRA CRS</name>
      <address>
        <city>Muang</city>
        <state>Chiang Rai</state>
        <zip>57000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prapokklao Hosp. CIPRA CRS</name>
      <address>
        <city>Chantaburi</city>
        <zip>22000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nakornping Hosp. CIPRA CRS</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50180</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Savang Vadhana Memorial Hosp. CIPRA CRS</name>
      <address>
        <city>Chonburi</city>
        <zip>20110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Srinagarind Hosp. CIPRA CRS</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bamrasnaradura Institute CIPRA CRS</name>
      <address>
        <city>Nonthaburi</city>
        <zip>11000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cambodia</country>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.hivnat.org</url>
    <description>Click here for more information about the HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)</description>
  </link>
  <reference>
    <citation>Lindsey JC, Malee KM, Brouwers P, Hughes MD; PACTG 219C Study Team. Neurodevelopmental functioning in HIV-infected infants and young children before and after the introduction of protease inhibitor-based highly active antiretroviral therapy. Pediatrics. 2007 Mar;119(3):e681-93. Epub 2007 Feb 12.</citation>
    <PMID>17296781</PMID>
  </reference>
  <reference>
    <citation>Nikolic-Djokic D, Essajee S, Rigaud M, Kaul A, Chandwani S, Hoover W, Lawrence R, Pollack H, Sitnitskaya Y, Hagmann S, Jean-Philippe P, Chen SH, Radding J, Krasinski K, Borkowsky W. Immunoreconstitution in children receiving highly active antiretroviral therapy depends on the CD4 cell percentage at baseline. J Infect Dis. 2002 Feb 1;185(3):290-8. Epub 2002 Jan 8.</citation>
    <PMID>11807710</PMID>
  </reference>
  <reference>
    <citation>Puthanakit T, Aurpibul L, Oberdorfer P, Akarathum N, Kanjananit S, Wannarit P, Sirisanthana T, Sirisanthana V. Hospitalization and mortality among HIV-infected children after receiving highly active antiretroviral therapy. Clin Infect Dis. 2007 Feb 15;44(4):599-604. Epub 2007 Jan 9.</citation>
    <PMID>17243067</PMID>
  </reference>
  <reference>
    <citation>Walker AS, Doerholt K, Sharland M, Gibb DM; Collaborative HIV Paediatric Study (CHIPS) Steering Committee. Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study. AIDS. 2004 Sep 24;18(14):1915-24.</citation>
    <PMID>15353977</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2005</study_first_submitted>
  <study_first_submitted_qc>October 4, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2005</study_first_posted>
  <last_update_submitted>December 2, 2013</last_update_submitted>
  <last_update_submitted_qc>December 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment Naive</keyword>
  <keyword>Treatment Initiation</keyword>
  <keyword>Infant</keyword>
  <keyword>Preschool Child</keyword>
  <keyword>Child</keyword>
  <keyword>Zidovudine</keyword>
  <keyword>AZT</keyword>
  <keyword>Retrovir</keyword>
  <keyword>3TC</keyword>
  <keyword>Lamivudine</keyword>
  <keyword>Epivir</keyword>
  <keyword>Nevirapine</keyword>
  <keyword>NVP</keyword>
  <keyword>Viramune</keyword>
  <keyword>Efavirenz</keyword>
  <keyword>EFV</keyword>
  <keyword>Sustiva</keyword>
  <keyword>Lopinavir/Ritonavir</keyword>
  <keyword>LPV/r</keyword>
  <keyword>Kaletra</keyword>
  <keyword>Nelfinavir</keyword>
  <keyword>NFV</keyword>
  <keyword>Viracept</keyword>
  <keyword>ABC</keyword>
  <keyword>Abacavir</keyword>
  <keyword>Ziagen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Nelfinavir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
    <mesh_term>Abacavir</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

